Peptide Array for Profiling of Autoantibodies in Non-small Cell Lung Cancer

用于分析非小细胞肺癌自身抗体的肽阵列

• 批准号: 7408695
• 负责人: Nada H Khattar
• 金额: $ 16.53万
• 依托单位: 20/20 GENESYSTEMS, INC.
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-28 至 2009-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7408695
• 关键词: Address; Advanced Development; Affinity Chromatography; Amylose; Antibodies; Area; Autoantibodies; Bacteria; Bacteriophages; Benign; Binding; Biological Assay; Biological Markers; Blood; Blood Tests; Blood specimen; Cancer Control; Cancer Patient; Clinical; Clinical Trials; Collaborations; Curative Surgery; Data; Development; Diagnosis; Diagnostic; Diagnostic Procedure; Disease; Doctor of Medicine; Doctor of Philosophy; Early Diagnosis; Elements; Escherichia coli; Exposure to; Floods; Glass; Goals; Grant; Head; Housing; Human Resources; Image; Immune system; Immunoassay; Intellectual Property; Invasive; Journals; Kentucky; Lead; Lung Neoplasms; Malignant Neoplasms; Malignant neoplasm of lung; Measurement; Measures; Medical; Methods; Neoplasm Metastasis; Nodule; Non-Small-Cell Lung Carcinoma; Oligonucleotides; Operative Surgical Procedures; Patients; Peptide Library; Peptides; Performance; Phage Display; Phase; Plasma; Population; Procedures; Production; Protein Microchips; Proteins; Publications; Purpose; Radiation; Rate; Receiver Operating Characteristics; Recombinants; Research Personnel; Rights; Risk; Running; Sampling; Screening procedure; Sensitivity and Specificity; Serum; Slide; Small Business Funding Mechanisms; Small Business Innovation Research Grant; Smoker; Specificity; Staging; Standardization; Techniques; Testing; Thoracic Oncology; Time; Translating; Tumor Markers; Universities; Validation; X-Ray Computed Tomography; base; cancer diagnosis; clinical application; cohort; concept; cost; improved; interest; lung cancer screening; maltose-binding protein; milligram; mortality; novel; peripheral blood; protein expression; prototype; scale up; tool; tumor; validation studies; vector

DESCRIPTION (provided by applicant): Approximately 135,000 new cases of non-small cell lung cancer (NSCLC) are diagnosed each year in the USA, yet only 20%-25% of those patients will be diagnosed at a sufficiently early stage to be cured by surgical or other procedures. When used in concert with radiographic imaging, a sensitive and specific blood test for NSCLC could be a clinically valuable and cost-effective tool for early diagnosis. The immune system responds to tumor-associated protein by secreting autoantibodies long before metastasis occurs. Autoantibody profiling for this important group of circulating tumor markers in peripheral blood has lead us to the identification of appropriate target peptides. We have developed a panel of 21 short peptides which were formatted as a protein microarray for use in a simple capture immunoassay. When probed with a blood sample the array can identify the presence of tumor-associated antibodies in NSCLC but not in normals with both sensitivity and a specificity exceeding 90% at early and later stages of the disease. As used to measure tumor-associated antibodies in serum from a cohort of cancer patients and risk-matched controls, this test affords predictive accuracy that exceeds that of currently available circulating NSCLC- associated protein markers. The overall purpose of this application is to prepare microarrays of a panel of peptide targets and to demonstrate that they enable measurement of autoantibody profiles that can distinguish cancer from normal blood samples with unprecedented sensitivity and specificity. Microarrays of the purified peptides will be used for rigorous optimization and standardization of all technical and clinical performance measures for the multi-target immunoassay. Our initial clinical application will be early detection of lung cancer, although multiple applications in lung cancer management are rational. Our data shows feasibility and proof of concept that supports the rationale for further development and testing of this approach. A subsequent Phase II application will lead to use of an appropriate platform for definitive marker validation trials for application to clinical screening of NSCLC. Thus the primary goal of this application is to develop a novel blood test for NSCLC that can be rapidly translated into clinical practice. A blood test for early detection of lung cancer could provide a cost-effective screening approach, and in concert with CT scanning would enable a viable strategy for reducing the severe mortality rate of this disease.

描述（由申请人提供）：美国每年诊断出约135，000例新的非小细胞肺癌（NSCLC）病例，但这些患者中只有20%-25%在足够早期的阶段被诊断出来，可以通过手术或其他方法治愈。当与放射成像配合使用时，敏感和特异的NSCLC血液检查可能是一种具有临床价值和成本效益的早期诊断工具。早在转移发生之前，免疫系统就通过分泌自身抗体来对肿瘤相关蛋白做出反应。外周血中这组重要的循环肿瘤标志物的自身抗体谱分析使我们鉴定出合适的靶肽。我们已经开发了一组21个短肽，其被格式化为蛋白质微阵列，用于简单的捕获免疫测定。当用血液样本探测时，该阵列可以识别NSCLC中肿瘤相关抗体的存在，但在疾病的早期和晚期，灵敏度和特异性均超过90%的正常人中则不能。当用于测量来自癌症患者和风险匹配对照组的血清中的肿瘤相关抗体时，该测试提供的预测准确度超过目前可用的循环NSCLC相关蛋白标志物的预测准确度。本申请的总体目的是制备一组肽靶标的微阵列，并证明它们能够测量自身抗体谱，从而以前所未有的灵敏度和特异性将癌症与正常血液样品区分开。纯化肽的微阵列将用于多靶点免疫测定的所有技术和临床性能指标的严格优化和标准化。我们最初的临床应用将是肺癌的早期检测，尽管在肺癌管理中的多种应用是合理的。我们的数据显示了可行性和概念证明，支持进一步开发和测试这种方法的基本原理。随后的II期申请将导致使用适当的平台进行确定性标志物验证试验，以应用于NSCLC的临床筛查。因此，本申请的主要目标是开发一种可快速转化为临床实践的新型NSCLC血液检测方法。用于肺癌早期检测的血液检测可以提供一种具有成本效益的筛查方法，并与CT扫描相结合，将成为降低这种疾病严重死亡率的可行策略。